From the blog

A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)

Primary Outcome Measures Incidence of Adverse Events (AEs) [ Time Frame: Up to 6 Months ] Time to onset of serious adverse events (SAEs) [ Time Frame: Up to 6 Months ] Time to onset of AEs [ Time Frame: Up to 6 Months ] Time to resolution of AEs [ Time Frame: Up to 6 Months ] Time to resolution of SAEs [ Time Frame: Up to 6[…]

Read More »

Checkmate 743 Shows Immunotherapy is Better for Mesothelioma Patients Who Cannot Receive Surgery

A clinical trial called Checkmate 743, which looks at the immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy), shows that the combination can create a better quality of life when compared with the chemotherapy drugs pemetrexed, cisplatin, and carboplatin. Patient reported outcomes were recently reported. People who took Opdivo and Yervoy[…]

Read More »

Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE) (MESO-IMMUNE)

Primary Outcome Measures Progression Free Survival assessed locally [ Time Frame: time from first dose of combination Nivolumab-Ipilimumab to first documentation of disease progression or to death from any cause evaluated through the total duration of the study (up to 48 months) ] Progression free survival as assessed by the investigator, defined as the[…]

Read More »

A Full Ban on Asbestos Was Recently Proposed

The Environmental Protection Agency just proposed a ban of all uses of chrysotile asbestos. It is the only asbestos that is imported into the country today. If banned, the material cannot be imported and the manufacturing, processing, distribution, and commercial use of it would be prohibited. The ban would be[…]

Read More »

DENDRITIC Cell Therapy Combined With SURGERY in Mesothelioma (ENSURE)

Primary Outcome Measures Number of participant who are alive and have completed (neo)adjuvant DCT (5 administrations) and surgery at week 15 (+4 weeks) without extended treatment-related delay, persisting grade 3-4 treatment side-effects or evidence of progression [Feasibility] [ Time Frame: 2 years ] To determine the feasibility of DCT with Mesopher performed before and[…]

Read More »

Platelet Count Can Potentially Influence Mesothelioma Survival

Mesothelioma is a hard-to-treat cancer. Usually chemotherapy, surgery, radiotherapy, and immunotherapy are used, but they do not do enough to save people’s lives. Scientists may have figured out why this is the case and could potentially have found the main causes that affect survival. These include stage of the tumor,[…]

Read More »

A Cancer Vaccine Could Potentially Help Mesothelioma Patients

Researchers are looking at a vaccine to maintain patient health after cancer treatment, which could be effective for mesothelioma in the future.  The vaccine is specifically made for each patient based on the individual’s biology. The trial is currently being tested on head and neck cancer. It does not usually[…]

Read More »

Researchers are Targeting Fibrosis to Improve Mesothelioma Care

Researchers have found that targeting lung fibrosis can help people with mesothelioma. People with mesothelioma usually suffer from fibrosis, which is the stiffening of tissue surrounding tumors. Certain drugs to treat mesothelioma are not very effective because the fibrosis prevents the drugs from penetrating the tumor. It also prevents the[…]

Read More »

Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

Primary Outcome Measures Dose-limiting Toxicity [ Time Frame: First 21 days of treatment. ] The incidence of DLTs during the DLT assessment period. Frequency and Severity of Adverse Events (AE) [ Time Frame: Screening to 90 days from last dose. ] The incidences and percentages of patients experiencing AEs summarized by NCI CTCAE version 5.0 grade and by[…]

Read More »

OT-101 Useful for COVID-19 and Cancers Like Mesothelioma

Researchers are looking at a new treatment for mesothelioma. It is a multimodal treatment (multiple treatments combined) consisting of the immunotherapy drug Keytruda and a new drug called OT-101. OT-101 is an antisense drug, which is a drug that blocks molecules that make certain proteins. The drug is also effective[…]

Read More »

Skip to content